Acute Leukemia News

  • Novartis's Kymriah Wins Speedy Reviews in U.S., Europe Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.
  • Venetoclax for Older Patients With AML? 'Remarkable' Response Older patients with AML, who are not eligible for intensive induction chemotherapy, can hope that combinations with venetoclax may eventually be viable options.
 

Acute Leukemia Perspective

 

Acute Leukemia Journal Articles